Status:
COMPLETED
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
Lead Sponsor:
Capital Medical University
Conditions:
Malignant Tumor
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.
Detailed Description
1. The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) . 2. Venous blood (4 ml) is collected from each subject and placed into tubes contai...
Eligibility Criteria
Inclusion
- histologically confirmed with malignant tumor;
- Age: 18-80 years;
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- At least one measurable lesion according to the RECIST criteria;
- Adequate bone marrow, cardiac, liver, and renal function;
- Life expectancy ≥2 months;
- Not received other anti-tumor treatment
- Informed consent signed
Exclusion
- previous history of other malignancies;
- Uncontrolled central nervous system metastases;
- Serious or uncontrolled concurrent medical illness.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01906632
Start Date
May 1 2013
End Date
June 30 2023
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital
Beijing, China, 100038